Adjuvant therapy for pancreas adenocarcinoma Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Chemoradiotherapy
  • Chemotherapy, Adjuvant
  • Pancreatic Neoplasms

abstract

  • Adjuvant therapy for pancreas adenocarcinoma in 2012 includes consideration of systemic therapy based on high level evidence and combined chemoradiotherapy based on less robust data. Current major adjuvant questions are examining the role of the addition of a second agent, either cytotoxic or targeted agent, to gemcitabine and whether or not the utilization of combined chemoradiotherapy improves overall survival. Progress to date has been modest and incremental in the adjuvant setting.

publication date

  • January 2013

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/jso.23230

PubMed ID

  • 22886586

Additional Document Info

start page

  • 78

end page

  • 85

volume

  • 107

number

  • 1